In companion-animal tablet production, the dioxopromethazine hydrochloride component is normally sifted through a 710 µm conical sieve to remove agglomerates formed during storage and transport. The terminal dosage form is a low-dose tablet core prepared by direct compression only when the API batch has a bulk density above 0.45 g/cm³ and a flow function coefficient above 4 on a ring shear tester; otherwise, wet granulation is triggered. The powder blend consists of silicified microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. In the transfer step, API is pre-blended with lactose monohydrate at 1:5 by mass for 10 minutes in a 200 L bin blender, then diluted to final mass. The final blend requires a blend uniformity acceptance value of ≤ 15 under USP <905>. Tablets are compressed on a rotary press using a 16-station B-tooling turret at 30–50 rpm, precompression force 6–10 kN, main compression force 12–18 kN, and target breaking force 50–80 N measured according to USP <1217>. In-process friability is held below 0.8% after 100 rotations. Terminally, the cores are film-coated with a low-permeability hydroxypropyl methylcellulose coating to reduce light-induced discoloration, then packed in PVC/PVDC/aluminium blisters. The coating weight gain is 2.5–3.5% relative to core mass. The exact label claim in milligrams per tablet is defined by the authorised summary of product characteristics; published data for this specific configuration remain limited, so pilot bioequivalence batches are used to confirm acceptable dissolution profiles against the reference product.

What Limits Terminal Sterilization of Dioxopromethazine Injection Fluids?

Sterile injectable solutions of dioxopromethazine are manufactured as 10–50 mL multidose or single-dose presentations for intramuscular or subcutaneous administration in cattle, pigs, and companion species. The aqueous vehicle is Water for Injections cooled to 25 ± 2 °C and sparged with filtered nitrogen until dissolved oxygen falls below 0.5 mg/L. The API is added under a stainless-steel impeller at 150–200 rpm; the concentration is fixed by the registered product licence and is not derived from a universal formulation ratio. Sodium chloride is added to achieve 0.9% w/v isotonicity, and the pH is adjusted with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide to 4.0–5.0. Terminal moist-heat sterilisation at 121 °C for 15 minutes is permissible only where forced-degradation studies demonstrate no colour shift, no particulate increase, and no chromatographic purity loss above 0.5% area. Because phenothiazine derivatives are prone to light-catalysed oxidation and radical-mediated degradation, many production lines select aseptic filtration through 0.45 µm and 0.22 µm PVDF membranes instead of terminal sterilisation. The path chosen must satisfy sterility assurance at 10⁻⁶ SAL under USP <71> and cumulative endotoxin limits per USP <85> or Ph. Eur. 5.1.10. The terminal finished product is filled into amber Type I glass vials or ampoules under nitrogen headspace, with residual headspace oxygen below 2.0% v/v, and sealed with bromobutyl rubber closures. Batch records require visible-particulate inspection according to USP <790>; subvisible particulate counts must comply with USP <788> for small-volume parenterals. The main processing bottleneck is oxidative colour development after oxygen ingress at the filling needle, therefore tank and line pressurisation with filtered nitrogen is maintained at 0.2–0.5 bar overpressure.

When Hard Gelatin Capsules Require Low-Moisture Granulation

For capsule presentations, direct powder filling is restricted when the blend equilibrium moisture content exceeds 2.0% w/w at 25 °C and 60% RH because the hydrochloride salt may cause gelatin shell embrittlement or crosslinking. The production route then shifts to dry granulation by roller compaction. The API is first blended with lactose monohydrate, pregelatinized starch, and talc; the API proportion in the dry granulate is registration-specific and normally controlled in the range 5–25% w/w, but no universal ratio is assigned to dioxopromethazine. The powder passes through a roller compactor with roll pressure 40–70 bar, roll speed 8–15 rpm, and screen milling at 1.0 mm. Granules are lubricated with magnesium stearate at 0.5–1.0% w/w for 3–5 minutes to avoid over-lubrication. The terminal product is filled into size 3 hard gelatin capsules using a dosator or tamping-pin machine at 50,000–120,000 capsules/hour; in-process mass uniformity must meet USP <905> acceptance value ≤ 15. Dissolution is tested under USP <711> with 0.1 M hydrochloric acid at 37 ± 0.5 °C. The finished capsules are packaged in aluminium/aluminium cold-form blisters to keep moisture ingress below 0.5 mg/day/blister at 40 °C/75% RH. The main failure mode observed on encapsulation lines is powder flood caused by electrostatics at low humidity; floor relative humidity is maintained at 40–50% RH.

In poultry drinking-water medication, a water-soluble powder containing dioxopromethazine hydrochloride is produced by tumble blending the API with lactose monohydrate or dextrose, citric acid, sodium citrate, and polyvinylpyrrolidone K30 as a dispersing agent. The finished sachet is sized to deliver a defined milligram-per-litre concentration when dissolved in a header tank or proportioner pump; the fill mass is calculated from the authorised dose per kilogram bodyweight and daily water intake, not from a fixed commercial ratio. A pre-dissolution check is conducted in target water at 5 g/L; if visible precipitation occurs at pH ≥ 6.8 or at carbonate hardness above 300 mg/L CaCO₃, the citrate buffer level is raised and the batch formula is adjusted through a registered deviation. The batch is blended in a 1,000 L V-blender at 12–18 rpm for 20–30 minutes. Terminal product is filled into foil-lined sachets under nitrogen; residual oxygen in headspace is limited to ≤ 2.0% v/v. Drinking-water stability is evaluated over 24 hours; chlorinated water at 1–3 ppm free chlorine may degrade the API, so water systems should be free of free chlorine or conditioned with a stabiliser before medication. Compliance with national medicated-water regulations and carrying-over limits for water lines is mandatory; published data for this specific water-soluble formulation are limited.

Particle-size segregation in roller-mixed feed premix lines

Premix production for medicated feedingstuffs uses dioxopromethazine as a low-volume active pre-diluted on calcium carbonate or wheat middling carrier to form a final premix concentration in the range of 5,000–50,000 mg/kg as defined by the veterinary marketing authorisation. The primary process risk is particle-size segregation and electrostatic adhesion of the API to polyethylene mixer walls. Therefore geometric pre-blending is carried out first at 1:10 API-to-carrier by mass in a 100 L tumbler for 15 minutes, then at 1:100 in a 1,000 L ribbon mixer at 20 rpm for 25 minutes. The carrier is selected to have D₉₀ ≤ 300 µm and loss on drying ≤ 1.0%. Batch homogeneity is confirmed by sampling 10 points with a thief probe; the target coefficient of variation is ≤ 5% for the active assay. The terminal product is discharged through a 2 mm screen into woven polypropylene bags with inner polyethylene liners and heat-sealed to exclude moisture. Premix manufacture is governed by Regulation (EU) 2019/4 for medicated feed, FDA 21 CFR Part 225 for medicated feed mill licensing, and relevant national carry-over rules; equipment cleanout uses validated wash-in-place or dry-vacuum procedures to avoid cross-contamination. The main batch failure mode observed in field audits is incomplete pre-blending when the API is dumped directly into the final mixer, producing assay values above 110% in the first and last bag.

Oral solution pH buffering and photodegradation controls

Oral solutions of dioxopromethazine are prepared as clear or slightly opalescent liquids in amber glass or amber polyethylene terephthalate bottles with tamper-evident caps and a metering pump. The vehicle is a cosolvent system of propylene glycol, glycerol, and purified water; API concentration is determined by the registered dose per kilogram and is typically prepared as a 1–10 mg/mL solution, but the exact value must reflect the authorised product file. Disodium edetate at 0.1% w/v is added to sequester trace metal ions, and sodium metabisulfite at 0.1% w/v is included as an oxygen scavenger. The pH is adjusted to 4.2 ± 0.2 with citric acid and sodium citrate, because hydroxide ions accelerate phenothiazine ring oxidation. The solution is filtered through a 10 µm polypropylene cartridge before filling. Finished product is held under visible light protection; ICH Q1B photostability testing should confirm no more than 5% total impurity increase after 1.2 million lux·h visible and 200 W·h/m² UV exposure. The terminal product is a 100 mL or 250 mL bottle with a low-density polyethylene dosing syringe. Microbial quality is controlled under Ph. Eur. 5.1.4 and preservative efficacy under USP <51>; the main operational limit is viscosity increase at storage below 5 °C, which can cause pump calibration drift above 5%.

Palatable granule intermediates are manufactured when a water-soluble powder is not suitable for direct administration and when field dosing requires appetite-masking. The direct process involves high-shear wet granulation of dioxopromethazine hydrochloride with dextrose, mannitol, microcrystalline cellulose, and hydroxypropyl methylcellulose as binder. The binder solution is prepared at 3–5% w/w polymer in purified water and added at 8–12% w/w of the dry mass. The wet mass is granulated in a high-shear mixer at impeller speed 200–300 rpm and chopper speed 1,500–2,500 rpm until a torque rise indicates agglomeration. Drying in a fluid-bed dryer uses inlet air at 55–65 °C until loss on drying is 1.5–2.5% w/w. The dried granules are calibrated through a 1.0 mm screen and packed into unit-dose sachets. The finished product is dispersed on a small quantity of feed or administered by oral syringe after reconstitution; exact dose per sachet is controlled by the marketing authorisation. Attainment of content uniformity is confirmed under USP <905>; the critical granule property is compressibility index, which should remain below 20% after drying to prevent sachet blockage. The main batch failure is overwetting of the binder, producing hard agglomerates above 2.5 mm and poor redispersibility in the field.